<DOC>
	<DOCNO>NCT00148460</DOCNO>
	<brief_summary>The objective trial compare efficacy safety single bolus TNK-tPA ( tenecteplase , Metalyse® ) compare rt-PA ( alteplase , Actilyse® ) Asian patient .</brief_summary>
	<brief_title>Trial Compare Efficacy Safety Single Bolus TNK-tPA ( Tenecteplase , Metalyse® ) With Accelerated Infusion Rt-PA ( Alteplase , Actilyse® ) Asian Patients With Acute Myocardial Infarction</brief_title>
	<detailed_description>This randomize ( 1:1 ) , open-label , multi-center , active-control , parallel-group study compare efficacy safety TNK-tPA ( tenecteplase , Metalyse® ) accelerate rt-PA ( alteplase , Actilyse® ) Asian patient AMI . The primary endpoint ( TIMI 3 Flow ) secondary endpoint ( TIMI frame count ) evaluate blinded manner core laboratory . Patients eligible trial meet inclusion exclusion criterion give inform consent randomize one two treatment group ( i.e . TNK-tPA accelerated rt-PA ) . The study period total 30-37 day include baseline , randomisation , study drug administration , in-hospital follow-up thirty-day follow-up . Coronary angiography perform 90 minute start study drug administration . 12-lead electrocardiogram ( ECGs ) obtain randomization , 60 75 minute 180 ± 15 minute start study drug administration , hospital discharge . If patient show rapid progressive hemodynamic deterioration 90 minute , rescue PTCA appropriate intervention perform discretion treat physician . Following analysis TIMI flow frame count study center , result carefully record CRFs . This data store compact disk film label subject 's study I.D . number . It send summary worksheet ECGs Angiographic Core Laboratory locate Leuven Coordinating Center ( LCC ) University Hospital Gasthuisberg ( Leuven , Belgium ) central evaluation . Study Hypothesis : The null hypothesis test difference two treatment group : TNK-tPA ( Tenecteplase , Metalyse® ) accelerate rt-PA ( Actilyse® ) , alternative difference . Comparison ( ) : The primary endpoint study TIMI 3 flow 90 minute start thrombolytic therapy , angiograms evaluate blinded manner core laboratory .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<criteria>1 . Age &gt; = 18 &lt; = 75 year . 2 . Asian origin . 3 . Ischemic discomfort &gt; = 30 minute duration . 4 . Onset acute myocardial infarction ( AMI ) symptom within 6 hour prior randomization . 5 . A twelve lead electrocardiogram ( ECG ) one following : ST segment elevation &gt; = 0.1 mV two limb lead ; &gt; = 0.2 mV two contiguous precordial lead indicative AMI . 6 . Ability give inform consent . 1 . Previous coronary artery bypass grafting ( CABG ) surgery . 2 . Cardiogenic shock ( e.g . systolic blood pressure [ SBP ] &lt; 90 mmHg ) . 3 . Systolic blood pressure ( SBP ) &gt; = 180 mmHg and/or diastolic blood pressure ( DBP ) &gt; = 110 mmHg current admission one reliable measurement prior randomization . 4 . Inability undergo cardiac catheterization . 5 . Significant bleed disorder either present within past 6 month . 6 . Major surgery , biopsy parenchymal organ , significant trauma within 3 month . 7 . Any minor head trauma and/or trauma occur onset current myocardial infarction . 8 . Use heparin , GPIIb/IIIa antagonists anticoagulant within last 2 week . 9 . Any known history stroke transient ischemic attack central nervous system structural damage ( i.e . neoplasm , aneurysm , intracranial surgery ) . 10 . Prolonged cardiopulmonary resuscitation ( &gt; 10 minute ) within 2 week . 11 . Pregnancy , lactation parturition within previous 30 day . Women childbearing potential must negative pregnancy test must use medically accepted method birth control ( i.e . uterine device , surgical sterilisation , progestogens alone ) . 12 . Previous treatment TNKtPA ( tenecteplase ) . 13 . Inability follow protocol comply followup . 14 . Drug abuse within last year . 15 . Participation another clinical trial within previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>